Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Liabilities and Shareholders Equity (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $122.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 4.97% to $122.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $495.4 million through Dec 2025, up 3.41% year-over-year, with the annual reading at $124.2 million for FY2025, 5.15% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $122.0 million at Aytu Biopharma, down from $125.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $265.7 million in Q2 2021, with the low at $115.8 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $149.3 million, with a median of $132.9 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 73.31% in 2021, then tumbled 48.2% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $223.8 million in 2021, then tumbled by 36.81% to $141.4 million in 2022, then dropped by 7.2% to $131.2 million in 2023, then decreased by 11.45% to $116.2 million in 2024, then rose by 4.97% to $122.0 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $122.0 million, $125.0 million, and $124.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.